Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,534,524
  • Shares Outstanding, K 192,114
  • Annual Sales, $ 2,854 M
  • Annual Income, $ 426,860 K
  • EBIT $ 596 M
  • EBITDA $ 685 M
  • 60-Month Beta 0.30
  • Price/Sales 4.04
  • Price/Cash Flow 18.47
  • Price/Book 1.90

Options Overview Details

View History
  • Implied Volatility 33.06% (-1.46%)
  • Historical Volatility 53.27%
  • IV Percentile 37%
  • IV Rank 22.13%
  • IV High 55.63% on 04/10/25
  • IV Low 26.64% on 03/24/25
  • Expected Move (DTE 17) 3.19 (5.36%)
  • Put/Call Vol Ratio 9.00
  • Today's Volume 20
  • Volume Avg (30-Day) 1,445
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 41,156
  • Open Int (30-Day) 41,568
  • Expected Range 56.30 to 62.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.76
  • Number of Estimates 10
  • High Estimate 1.02
  • Low Estimate 0.66
  • Prior Year 0.72
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.90 +16.46%
on 12/15/25
63.89 -7.22%
on 12/19/25
+3.35 (+5.99%)
since 11/28/25
3-Month
50.76 +16.78%
on 11/07/25
63.89 -7.22%
on 12/19/25
+5.12 (+9.45%)
since 09/30/25
52-Week
50.76 +16.78%
on 11/07/25
73.51 -19.36%
on 03/07/25
-6.17 (-9.43%)
since 12/30/24

Most Recent Stories

More News
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics...

FOLD : 14.24 (-0.07%)
BMRN : 59.06 (-1.63%)
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BMRN : 59.06 (-1.63%)
A $4.8 Billion Reason to Buy BioMarin Stock Today

BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.

FOLD : 14.24 (-0.07%)
BMRN : 59.06 (-1.63%)
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

BMRN : 59.06 (-1.63%)
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Gain Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth...

FOLD : 14.24 (-0.07%)
BMRN : 59.06 (-1.63%)
1 Oversold Stock Primed to Rebound and 2 That Underwhelm

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

SHW : 323.64 (-0.49%)
BMRN : 59.06 (-1.63%)
CHD : 84.57 (-0.90%)
2 Reasons to Like BMRN and 1 to Stay Skeptical

2 Reasons to Like BMRN and 1 to Stay Skeptical

BMRN : 59.06 (-1.63%)
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

BMRN : 59.06 (-1.63%)
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

ABT : 124.90 (+0.26%)
BMRN : 59.06 (-1.63%)
ABBV : 229.43 (-0.61%)
DXCM : 67.09 (-0.56%)
BIIB : 176.21 (-0.35%)
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

BMRN : 59.06 (-1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 61.58
2nd Resistance Point 61.08
1st Resistance Point 60.56
Last Price 59.06
1st Support Level 59.54
2nd Support Level 59.04
3rd Support Level 58.52

See More

52-Week High 73.51
Fibonacci 61.8% 64.82
Fibonacci 50% 62.14
Fibonacci 38.2% 59.45
Last Price 59.06
52-Week Low 50.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar